• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1.

作者信息

Bhattacharyya J, Mihara K, Kitanaka A, Yanagihara K, Kubo T, Takei Y, Kimura A, Takihara Y

出版信息

Blood Cancer J. 2012 Jun;2(6):e75. doi: 10.1038/bcj.2012.21. Epub 2012 Jun 22.

DOI:10.1038/bcj.2012.21
PMID:22829977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3389163/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73b1/3389163/a659d5fccb74/bcj201221f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73b1/3389163/a659d5fccb74/bcj201221f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73b1/3389163/a659d5fccb74/bcj201221f1.jpg

相似文献

1
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1.使用针对CD38的嵌合受体进行T细胞免疫疗法，在根除由BMI-1诱导的过表达生存素的化疗耐药性B细胞淋巴瘤细胞方面是有效的。
Blood Cancer J. 2012 Jun;2(6):e75. doi: 10.1038/bcj.2012.21. Epub 2012 Jun 22.
2
Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.针对B细胞非霍奇金淋巴瘤中CD38的嵌合受体激活T细胞介导的免疫疗法。
J Immunother. 2009 Sep;32(7):737-43. doi: 10.1097/CJI.0b013e3181adaff1.
3
Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.嵌合受体抗 CD19 或抗 CD38 联合利妥昔单抗的 T 细胞免疫治疗对 B 细胞非霍奇金淋巴瘤的协同和持续作用。
Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30.
4
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.用于治疗多发性骨髓瘤的CD38嵌合抗原受体工程化T细胞的临床前评估。
Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8.
5
T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.携带抗 CD19 和/或抗 CD38 嵌合抗原受体的 T 细胞能有效消除原发性双打击淋巴瘤细胞。
J Hematol Oncol. 2017 Jun 8;10(1):116. doi: 10.1186/s13045-017-0488-x.
6
Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.阻断 T 细胞中 CD38 驱动的自相残杀可增强 CD38 特异性嵌合抗原受体 T 细胞的抗肿瘤活性。
J Genet Genomics. 2019 Aug 20;46(8):367-377. doi: 10.1016/j.jgg.2019.06.007. Epub 2019 Aug 13.
7
Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma.靶向CD38的新型嵌合抗原受体T细胞对多发性骨髓瘤治疗作用的表征
Front Oncol. 2021 Aug 26;11:703087. doi: 10.3389/fonc.2021.703087. eCollection 2021.
8
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.使用针对CD38的嵌合受体进行T细胞免疫疗法可有效消除骨髓瘤细胞。
Leukemia. 2012 Feb;26(2):365-7. doi: 10.1038/leu.2011.205. Epub 2011 Aug 12.
9
Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.优化犬 CD20 嵌合抗原受体 T 细胞的制备及其对 B 细胞淋巴瘤的体外细胞毒性活性。
Vet Comp Oncol. 2020 Dec;18(4):739-752. doi: 10.1111/vco.12602. Epub 2020 Jun 1.
10
All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia.全反式维甲酸增强了急性髓系白血病中具有抗CD38嵌合抗原受体的T细胞的细胞毒性作用。
Clin Transl Immunology. 2016 Dec 9;5(12):e116. doi: 10.1038/cti.2016.73. eCollection 2016 Dec.

引用本文的文献

1
Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma.靶向CD38的新型嵌合抗原受体T细胞对多发性骨髓瘤治疗作用的表征
Front Oncol. 2021 Aug 26;11:703087. doi: 10.3389/fonc.2021.703087. eCollection 2021.
2
The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy.CD38 在淋巴瘤中的多面性：从肿瘤微环境细胞相互作用到免疫治疗获得性耐药。
Cells. 2020 Mar 26;9(4):802. doi: 10.3390/cells9040802.
3
Immunotherapies targeting CD38 in Multiple Myeloma.

本文引用的文献

1
Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.BMI-1 的过表达通过稳定 survivin 的表达与 B 细胞淋巴瘤细胞的耐药性相关。
Cancer Sci. 2012 Jan;103(1):34-41. doi: 10.1111/j.1349-7006.2011.02121.x. Epub 2011 Nov 20.
2
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.嵌合抗原受体 T 细胞具有强大的抗肿瘤作用，并能在晚期白血病患者中建立记忆。
Sci Transl Med. 2011 Aug 10;3(95):95ra73. doi: 10.1126/scitranslmed.3002842.
3
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
靶向多发性骨髓瘤中CD38的免疫疗法。
Oncoimmunology. 2016 Aug 5;5(11):e1217374. doi: 10.1080/2162402X.2016.1217374. eCollection 2016.
4
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.用于治疗多发性骨髓瘤的CD38嵌合抗原受体工程化T细胞的临床前评估。
Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8.
5
Expression of microRNA-452 via adenoviral vector inhibits non-small cell lung cancer cells proliferation and metastasis.通过腺病毒载体表达微小RNA-452可抑制非小细胞肺癌细胞的增殖和转移。
Tumour Biol. 2016 Jun;37(6):8259-70. doi: 10.1007/s13277-015-4725-z. Epub 2015 Dec 30.
嵌合抗原受体修饰的 T 细胞治疗慢性淋巴细胞白血病。
N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/NEJMoa1103849. Epub 2011 Aug 10.
4
Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.嵌合受体抗 CD19 或抗 CD38 联合利妥昔单抗的 T 细胞免疫治疗对 B 细胞非霍奇金淋巴瘤的协同和持续作用。
Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30.
5
A systematic review of occupational exposure to particulate matter and cardiovascular disease.一项关于职业暴露于颗粒物与心血管疾病的系统评价。
Int J Environ Res Public Health. 2010 Apr;7(4):1773-806. doi: 10.3390/ijerph7041773. Epub 2010 Apr 19.
6
The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment.在中国接受 CHOP 或 R-CHOP 治疗的初治弥漫性大 B 细胞淋巴瘤患者中，免疫组织化学亚型的预后价值。
Ann Hematol. 2010 Feb;89(2):171-7. doi: 10.1007/s00277-009-0799-2. Epub 2009 Aug 11.
7
Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.针对B细胞非霍奇金淋巴瘤中CD38的嵌合受体激活T细胞介导的免疫疗法。
J Immunother. 2009 Sep;32(7):737-43. doi: 10.1097/CJI.0b013e3181adaff1.
8
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.在标准化疗基础上加用利妥昔单抗可提高弥漫性大B细胞淋巴瘤生发中心B细胞样和非生发中心B细胞样亚型的生存率。
J Clin Oncol. 2008 Oct 1;26(28):4587-94. doi: 10.1200/JCO.2007.15.9277. Epub 2008 Jul 28.
9
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.伴有t(14;18)和8q24/c-MYC重排的弥漫性大B细胞淋巴瘤的临床表现及预后
Haematologica. 2007 Oct;92(10):1335-42. doi: 10.3324/haematol.11305.
10
Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma.利妥昔单抗联合化疗可提高未治疗的非生发中心型弥漫性大B细胞淋巴瘤患者的生存率。
Leukemia. 2007 Dec;21(12):2563-6. doi: 10.1038/sj.leu.2404844. Epub 2007 Jun 28.